© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
October 04, 2021
In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
October 01, 2021
In a study presented at the 2021 AUA annual meeting, Behfar Ehdaie, MD, MPH, and colleagues assessed the efficacy of focal therapy in treating patients with grade group 2 or 3 prostate cancers.
September 30, 2021
Dharam Kaushik, MD, and a team of investigators are the first to examine the benefits of perioperative yoga in patients diagnosed with localized prostate cancer.
In a recent study presented at the 2021 AUA Annual Meeting, Laurence Klotz, MD, FRCSC, and a team of investigators determined the accuracy of the new miR Sentinel PCC4 Test, a urinalysis of low- to high-grade prostate cancer in men.
September 28, 2021
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it could change the future of prostate cancer testing.
September 25, 2021
“Our data shows that in newly diagnosed men with prostate cancer, yoga improved quality of life [as well as] some immune markers, and [lowered] inflammation,” says Dharam Kaushik, MD.
September 24, 2021
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
September 23, 2021
“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.
“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.
September 22, 2021
“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.